Phase lb dose-finding study of axitinib plus pembrolizumab in treatment-naive patients with advanced renal cell carcinoma

被引：0
|
作者：
Choueiri, Toni K. [1 ]
Plimack, Elizabeth R. [2 ]
Gupta, Shilpa [3 ]
Puzanov, Igor [4 ]
Mcdermott, David F. [5 ]
Tarazi, Jamal [6 ]
Keefe, Stephen [7 ]
Rosbrook, Brad [6 ]
Atkins, Michael B. [8 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[3] Univ Minnesota, Mason Canc Ctr, Minneapolis, MN USA
[4] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[5] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[6] Pfizer Oncol, San Diego, CA USA
[7] Merck Res Labs, N Wales, PA USA
[8] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA
来源：
BJU INTERNATIONAL | 2015年 / 116卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：5 / 5
页数：1
相关论文
共 50 条
  • [21] Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial
    Atkins, Michael B.
    Plimack, Elizabeth R.
    Puzanov, Igor
    Fishman, Mayer N.
    McDermott, David F.
    Cho, Daniel C.
    Vaishampayan, Ulka
    George, Saby
    Tarazi, Jamal C.
    Duggan, William
    Perini, Rodolfo
    Thakur, Mahgull
    Fernandez, Kathrine C.
    Choueiri, Toni K.
    EUROPEAN JOURNAL OF CANCER, 2021, 145 : 1 - 10
  • [22] Hypopituitarism induced by pembrolizumab plus axitinib in the treatment of metastatic renal cell carcinoma: A case report
    Hanawa, Kazushi
    Sawada, Norifumi
    Aikawa, Junki
    Otake, Yuko
    Kasai, Yoshifumi
    Mochizuki, Keito
    Shimura, Hiroshi
    Mochizuki, Takanori
    Kira, Satoru
    Mitsui, Takahiko
    ONCOLOGY LETTERS, 2024, 27 (02)
  • [23] A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma
    McGregor, Bradley
    Geynisman, Daniel M.
    Burotto, Mauricio
    Suarez, Cristina
    Bourlon, Maria T.
    Barata, Pedro C.
    Gulati, Shuchi
    Huo, Stephen
    Ejzykowicz, Flavia
    Blum, Steven I.
    Del Tejo, Viviana
    Hamilton, Melissa
    May, Jessica R.
    Du, Ella X.
    Wu, Aozhou
    Kral, Pavol
    Ivanescu, Cristina
    Chin, Andi
    Betts, Keith A.
    Lee, Chung-Han
    Choueiri, Toni K.
    Cella, David
    Porta, Camillo
    EUROPEAN UROLOGY ONCOLOGY, 2023, 6 (03): : 339 - 348
  • [24] Axitinib for the treatment of advanced renal cell carcinoma
    Akaza, Hideyuki
    Fukuyama, Tomofusa
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (02) : 283 - 297
  • [25] Outcomes for patients in the pembrolizumab plus axitinib arm with advanced renal cell carcinoma (RCC) who completed two years of treatment in the phase III KEYNOTE-426 study.
    Plimack, Elizabeth R.
    Powles, Thomas
    Bedke, Jens
    Pouliot, Frederic
    Stus, Viktor
    Waddell, Tom
    Gafanov, Rustem
    Nosov, Dmitry
    Alekseev, Boris
    McDermott, Raymond S.
    Markus, Maurice
    Tartas, Sophie
    Kryzhanivska, Anna
    Bondarenko, Igor
    Szczylik, Cezary
    Lin Jianxin
    Perini, Rodolfo F.
    Molife, Rhoda L.
    Atkins, Michael B.
    Rini, Brian, I
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [26] Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study
    Lee, Chung-Han
    Shah, Amishi Yogesh
    Rasco, Drew
    Rao, Arpit
    Taylor, H. Matthew
    Di Simone, Christopher
    Hsieh, J. James
    Pinto, Alvaro
    Shaffer, R. David
    Sarrio, Regina Girones
    Cohn, Allen Lee
    Vogelzang, J. Nicholas
    Bilen, Mehmet Asim
    Ribe, Sara Gunnestad
    Goksel, Musaberk
    Tennoe, Oyvind Krohn
    Richards, Donald
    Sweis, F. Randy
    Courtright, Jay
    Heinrich, Daniel
    Jain, Sharad
    Wu, Jane
    Schmidt, V. Emmett
    Perini, F. Rodolfo
    Kubiak, Peter
    Okpara, E. Chinyere
    Smith, D. Alan
    Motzer, J. Robert
    LANCET ONCOLOGY, 2021, 22 (07): : 946 - 958
  • [27] Fruquintinib Plus Sintilimab in Patients with Treatment-Naive and Previously Treated Advanced Renal Cell Carcinoma: Results from a Phase Ib/II Clinical Trial
    Xu, Hua
    Yao, Xin
    He, Zhisong
    Luo, Hong
    Li, Guiling
    Guo, Jianming
    Diao, Lei
    Fan, Yu
    Li, Yuan
    Fan, Jiquan
    Hu, Xiaoyi
    Lu, Puhan
    Shi, Haiyan
    Chen, Keyan
    Tan, Panfeng
    Fan, Songhua
    Shi, Michael
    Su, Weiguo
    Ye, Dingwei
    TARGETED ONCOLOGY, 2025, 20 (01) : 113 - 125
  • [28] A Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Versus Pembrolizumab Plus Axitinib and Versus Avelumab Plus Axitinib in First-Line Treatment of Advanced Renal Cell Carcinoma
    Shay, Rebecca
    Nicklawsky, Andrew
    Gao, Dexiang
    Lam, Elaine T.
    CLINICAL GENITOURINARY CANCER, 2021, 19 (04) : 370 - +
  • [29] Pathologic complete response with pembrolizumab plus axitinib in metastatic renal cell carcinoma
    Shimizu, Kazuki
    Tamada, Satoshi
    Matsuoka, Yudai
    Go, Ishun
    Okumura, Satoshi
    Ogawa, Masao
    Ohmachi, Tetsuji
    INTERNATIONAL CANCER CONFERENCE JOURNAL, 2022, 11 (03) : 205 - 209
  • [30] Phase Ib Study (COSMIC-021) of Cabozantinib in Combination With Atezolizumab: Results of the Dose-Escalation Stage in Patients With Treatment-Naive Advanced Renal Cell Carcinoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (12) : 8 - 10
12345